

# UC Davis

## UC Davis Previously Published Works

### Title

Sostdc1 deficiency accelerates fracture healing by promoting the expansion of periosteal mesenchymal stem cells.

### Permalink

<https://escholarship.org/uc/item/10c8v4h9>

### Authors

Collette, Nicole M  
Yee, Cristal S  
Hum, Nicholas R  
et al.

### Publication Date

2016-07-01

### DOI

10.1016/j.bone.2016.04.005

Peer reviewed



Published in final edited form as:

Bone. 2016 July ; 88: 20–30. doi:10.1016/j.bone.2016.04.005.

## Sostdc1 Deficiency Accelerates Fracture Healing by Promoting the Expansion of Periosteal Mesenchymal Stem Cells

Nicole M. Collette<sup>1</sup>, Cristal S. Yee<sup>1,2</sup>, Nicholas R. Hum<sup>1</sup>, Deepa K. Muruges<sup>1</sup>, Blaine A. Christiansen<sup>3</sup>, LiQin Xie<sup>4</sup>, Aris N. Economides<sup>4</sup>, Jennifer O. Manilay<sup>2</sup>, Alexander G. Robling<sup>5</sup>, and Gabriela G. Loots<sup>1,2,\*</sup>

<sup>1</sup>Biology and Biotechnology Division, Lawrence Livermore National Laboratory, 7000 East Avenue, L-452, Livermore, CA 94550, USA

<sup>2</sup>Molecular and Cell Biology Unit, School of Natural Sciences, University of California at Merced, Merced, CA, USA

<sup>3</sup>University of California Davis Medical Center, Sacramento, CA, USA

<sup>4</sup>Regeneron Pharmaceuticals, Tarrytown, NY, USA

<sup>5</sup>Indiana University, Indianapolis, IN, USA

### Abstract

Loss of *Sostdc1*, a growth factor paralogous to *Sost*, causes the formation of ectopic incisors, fused molars, abnormal hair follicles, and resistance to kidney disease. *Sostdc1* is expressed in the periosteum, a source of osteoblasts, fibroblasts and mesenchymal progenitor cells, which are critically important for fracture repair. Here, we investigated the role of *Sostdc1* in bone metabolism and fracture repair. Mice lacking *Sostdc1* (*Sostdc1*<sup>-/-</sup>) had a low bone mass phenotype associated with loss of trabecular bone in both lumbar vertebrae and in the appendicular skeleton. In contrast, *Sostdc1*<sup>-/-</sup> cortical bone measurements revealed larger bones with higher BMD, suggesting that *Sostdc1* exerts differential effects on cortical and trabecular bone. Mid-diaphyseal femoral fractures induced in *Sostdc1*<sup>-/-</sup> mice showed that the periosteal population normally positive for *Sostdc1* rapidly expands during periosteal thickening and these cells migrate into the fracture callus at 3 days post fracture. Quantitative analysis of mesenchymal stem cell (MSC) and osteoblast populations determined that MSCs express *Sostdc1*, and that *Sostdc1*<sup>-/-</sup> 5 day calluses harbor >2-fold more MSCs than fractured wildtype controls. Histologically a fraction of *Sostdc1*-positive cells also expressed nestin and  $\alpha$ -smooth muscle actin, suggesting that *Sostdc1* marks a population of osteochondral progenitor cells that actively participate in callus formation and bone

\* Author for correspondence (loots1@llnl.gov).

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Disclosures: None

#### Author Contributions

NMC and GGL conceptualized the hypothesis, designed the experiments, analyzed data and wrote the article. NMC, CSY, DKM, NRH, LX, ANE, JOM, AGR, BAC conducted experiments and analyzed data. NMC, CSY and DKM conducted animal study and animal care.

repair. Elevated numbers of MSCs in D5 calluses resulted in a larger, more vascularized cartilage callus at day 7, and a more rapid turnover of cartilage with significantly more remodeled bone and a thicker cortical shell at 21 days post fracture. These data support accelerated or enhanced bone formation/remodeling of the callus in *Sostdc1*<sup>-/-</sup> mice, suggesting that *Sostdc1* may promote and maintain mesenchymal stem cell quiescence in the periosteum.

## Keywords

Sostdc1; Wise; Ectodin; Sost-like; Usag-1; Sost; Wnt signaling; periosteum; bone regeneration; fracture repair

## 1. Introduction

Optimal fracture repair requires contribution from surrounding tissues, yet we know very little about the interactions between bone, muscle, vasculature, and the periosteum [1–3]. In particular the periosteum, a thin tissue that covers the outer cortical bone surface, contains a reservoir of progenitor cells that contribute to bone repair; further, periosteal grafts and alpha-smooth muscle actin ( $\alpha$ -SMA)-positive cells integrate into the callus after fracture<sup>[3, 4]</sup>. Other *in vivo* studies have shown that periosteal and perivascular cells migrate into developing bone and bone undergoing repair, and differentiate into osteoblasts [4, 5].

*Sostdc1*, a paralog of *Sost* also known by several other names including *Sost-Like*, *Wise*, *Ectodin* and *Usag-1* arose by segmental gene duplication and was previously studied in the context of tooth development, kidney disease, cancer progression, hair follicle formation, and embryo implantation [6–11]. Recently, we have shown that *Sostdc1* also contributes to limb morphogenesis [12], and its expression in the periosteum suggests that it may also play a role in bone maintenance and repair. However, the role of *Sostdc1* in fracture healing has not been investigated. *Sostdc1* has been described as both a Bmp and a Wnt antagonist in a context-dependent manner [13], and it interacts with Lpr4, 5, and 6 Wnt co-receptors and with Bmp ligands [6, 13–16], *in vivo*. While *Sostdc1* shares 55% protein sequence homology to its paralog *Sost*, it reportedly displays higher specificity for the Lrp4 co-receptor [14], in contrast to the preferred binding to the Lrp5 and 6 co-receptors by *Sost* [17, 18]. Mesenchyme-derived *Sostdc1* inhibits Wnt signaling in the epithelium through the activation of Hedgehog signaling, which in turn suppresses Wnt signaling *via* *Sostdc1* up-regulation in the mesenchyme [12, 19].

To determine the contribution of *Sostdc1* to bone metabolism and repair, we characterized trabecular and cortical bone structure and fracture healing program in *Sostdc1*<sup>-/-</sup> mice. Herein we show data in support of *Sostdc1* as both an anabolic and a catabolic agent, with distinct compartmental contributions to bone metabolism, wherein *Sostdc1* deficiency results in a substantial loss of trabecular bone and a significant gain in cortical bone. We find that *Sostdc1* marks a population of progenitor stem cells of mesenchymal origin that rapidly expands after injury and populates the callus up to 7 days post-fracture. In addition, we show that in the early stages of fracture repair, *Sostdc1*<sup>-/-</sup> cells increase  $\beta$ -catenin-dependent Wnt signaling and promote callus formation *via* enhanced progenitor cell migration and differentiation. At early stages post-fracture (3 and 7 days post fracture), *Sostdc1*<sup>-/-</sup> mice

show enhanced intramembranous bone formation and neovascularization compared to controls, along with dramatically elevated numbers of cells expressing nestin,  $\alpha$ -SMA, and SP7/Osterix. Although the genetic loss of *Sostdc1* results in trabecular bone loss, *Sostdc1* may represent a novel therapeutic target for bone formation defects that require rapid intramembranous bone formation to stabilize structural integrity.

## 2. Material and Methods

### 2.1. Animals and Femoral Fracture Model

*Sostdc1*<sup>-/-</sup> mice have been previously described [12]. Stabilized femoral fractures were produced in *Sostdc1*<sup>-/-</sup>, *Sostdc1*<sup>+/-</sup> and *C57B/L6* wildtype control male mice at 8-weeks of age using an Einhorn closed fracture model, as previously described [20]. Fractures were confirmed radiologically (CareStream *in vivo* MS-FX) at the time of surgery and femora were harvested at days 3, 5, 7, 10, 14, 21 and 28 post-fracture for subsequent analysis. Animal studies were approved by the Institutional Animal Care and Use Committee of Lawrence Livermore National Laboratory (Livermore, CA, USA).

### 2.2. LacZ and Immunohistological Staining

The *Sostdc1* knockout allele was generated by replacing both *Sostdc1* exons with an in-frame *LacZ* reporter. *LacZ* stains were performed on fixed tissues (fractured and intact femora at days 3, 7, 10, 14, and 21 post-fracture, n=3 per group, per time point, male mice) of *Sostdc1*<sup>+/-</sup> and *Sostdc1*<sup>-/-</sup> mice as previously described [21] with minor modifications. Tissues were fixed and then decalcified in 0.5M EDTA until endpoint confirmation by radiotranslucency. *LacZ* stain was followed by fixation, dehydration, and paraffin embedding for sectioning (6 $\mu$ m) and histology. Sections were counterstained with alcoholic eosin. For immunostains, femora from *Sostdc1*<sup>-/-</sup> or *Sostdc1*<sup>+/-</sup> mice, with or without fractures (n=3 per group of male mice, per time point), were fixed for 72 hours in 10% neutral buffered formalin at 4°C, followed by decalcification and sectioning as above. Antigen retrieval was conducted using Uni-trieve (Innovex) for 30 minutes at 65°C unless otherwise stated. Antigen retrieval for activated  $\beta$ -catenin (Millipore, 05-665) included digestion with Proteinase K (15 $\mu$ g/ml) for 20 minutes at 37°C followed by Rodent Block M (Biocare Medical, 50-832-64). Primary antibodies for  $\alpha$ -Smooth Muscle Actin ( $\alpha$ -SMA) (abcam, ab5694),  $\beta$ -galactosidase (abcam, ab9361), nestin, (abcam, ab6142) and SP7/osterix (abcam, ab22552) were incubated on slides overnight at RT followed by secondary antibody conjugated with Alexa Fluor 488 or 596 (Molecular Probes) for green and red stains, respectively. Immunostained slides were mounted with Prolong Gold with DAPI (Molecular Probes) for imaging. Images were obtained with a color CCD QIClick camera and ImagePro Plus V7.0 imaging software. Quantification of immunostains was performed using Image J software, utilizing the Analyze Particles tool, to determine the total area of stem cell marker-positive cells. A minimum of 50 images of similar callus regions from n=3 animals per group per time point were used. This quantification was not absolute, but provided an estimate for the magnitude of the observed differences seen between genotypes.

### 2.3. Micro-Computed Tomography ( $\mu$ CT) of intact and fracture calluses

*Sostdc1*<sup>-/-</sup> and *C57B/L6* wildtype control male mice at 5.5 months of age were analyzed by  $\mu$ CT at the distal femoral metaphysis, femoral mid-diaphysis, and L4 vertebral body to determine bone micro-structure parameters (n=6-10 per group) ( $\mu$ CT 35, SCANCO, Brüttisellen, Switzerland) according to the guidelines for  $\mu$ CT analysis of rodent bone structure [22]: energy 55 kVp, intensity 114 mA, integration time 900 ms, 6  $\mu$ m nominal voxel size. For fracture analysis, callus measurements were compared at 28 days post fracture between *Sostdc1*<sup>-/-</sup> and *WT*, 3 month old, age-matched animals. Intact femora of *Sostdc1*<sup>-/-</sup> and *C57B/L6* animals were also measured at 12 weeks of age. The threshold for “bone” was set at 350 (35% of maximum value), which is approximately equal to 567 mg HA/cm<sup>3</sup>. Callus volume measurements (CV) excluded the native bone volume.

### 2.4. Bone Histomorphometry Measurements

Dynamic bone histomorphometry measurements were obtained from femoral mid-diaphyses of 12 weeks and 5.5 month old male mice. Mice were injected with 30 mg/kg alizarin red and 10 mg/kg calcein 10- and 3- days before euthanasia. Femora were dissected and fixed in 10% neutral phosphate-buffered formaldehyde for 24 hours. Bone histomorphometry was performed using semiautomatic image analysis as described [23, 24].

### 2.5. Bone Strength Measurements

Fractured and uninjured contralateral femora of male mice were mechanically tested in torsion to quantify biomechanical properties of bone (n=8-10 per group). Femora were rehydrated in isotonic saline for 5-10 minutes prior to testing, and were kept hydrated throughout testing. Both ends of each femur were embedded in Wood’s metal alloy blocks with a testing length of 6 mm, then mounted in a materials testing system (Bose ELF 3200, Eden Prairie, MN) with torsion motor (Exlar SLM Series). An axial load of 3-4 N was applied, then 10 preconditioning torsion cycles were applied to  $\pm 5^\circ$  at 0.1 Hz, followed by a single cycle to failure in external rotation at 1°/s. Torque and rotational displacement data were collected at 50 Hz. The failure cycle was used to calculate torsional stiffness, ultimate torque, and rotation at ultimate torque.

### 2.6. Analysis of Stromal Bone Cells

Unfractured and fractured femora at 8-10 weeks of age male mice were dissected and placed in 1x Hank’s Balanced Salt Solution (HBSS) pH7.2 without serum. Bone digestion was performed as described [25]. Briefly, bones were crushed in 1x HBSS using a mortar and pestle and bone marrow cells were washed away from the bone chips. The bone chips were then transferred to a 50 ml conical tube with 2.0 ml of 3.0 mg/ml Type I Collagenase (Worthington, Lakewood, NJ) and digested in a shaker at 110 rpm at 37°C for 1 hour. The supernatant from the digest was transferred through a 70 micron filter into a fresh conical tube, the remaining bone chips were rinsed with additional 1x HBSS containing 2% FCS, which was added to the supernatant. Cells were then pelleted at 1200 rpm for 5 minutes at 4°C. Live cell yield was counted using a hemocytometer and Trypan blue staining. Cells were then prepared for flow cytometric analysis. Cells were transferred to 96 well V-bottom plates and stained with an antibody cocktail containing anti CD16/32 (clone 93), and PE-

Cy7 conjugated anti-CD3 (2C11), CD4 (GK1.5), CD8 (53.6.7), CD11b (M1/70), CD19 (6D5), NK1.1 (PK136), Ter119 (TER119), and Gr1 (RB6-8C3) in 50  $\mu$ l volume of FACS Buffer for at least 15 minutes at 4°C. Cells were then washed and pelleted for 5 minutes at 2000 rpm, and stained with a second antibody cocktail containing CD45-eFluor 450 (30F11), Sca1-FITC (D7), CD31-APC (390), and either CD51-biotin (RMV-7) or isotype-matched biotin control Ab. Cells were incubated at 4°C for 15 minutes, washed, and pelleted. Lastly, cells were stained with streptavidin-PE for 5 minutes, washed, pelleted and resuspended in FACS buffer for analysis. Propidium iodide was added to the samples before analysis as a viability stain. Live cells were analyzed on a BD LSR II flow cytometric analyzer and data analysis was performed using FlowJo software. Antibodies were purchased from BioLegend and eBioscience.

## 2.7. Gene Expression Analysis

Bone derived mesenchymal stem cells (MSCs) cells were stained as above, except that Sca1-Brilliant Violet 510 (BioLegend) was used. MSCs, OBs and endothelial cells were isolated using the BD FACS Aria II flow cytometry sorter, and then pelleted and resuspended in Trizol (Qiagen). Total RNA was purified using RNeasy mini Kit (Qiagen) according to manufacturer's protocol. Samples were analyzed for purity and concentration using a NanoDrop 2000c (Thermo Scientific). Superscript III First-Strand Synthesis System (Invitrogen) was used with oligo dT primers for reverse transcription according to manufacturer's protocol. Real-time quantitative PCR was then performed with SYBR Select Master Mix (Applied Biosystems) using a Applied Biosystems 7900HT Fast Real-Time PCR System with the following cycling conditions: 50°C for 2 min for Sybr then 95°C for 3 min (2 min for SYBR), followed by 40 cycles of 95°C for 3s (10s for SYBR) and 30s at 60°C. Reactions were run on a 2% agarose gel then DNA fragments imaged under UV light. Primers:  $\beta$ -galactosidase forward ACGGCCAGGACAGTCGTTTG and reverse CCGCTCATCCGCCACATATC; GAPDH forward CCAATGTGTCCGTCGTGGATCT and reverse CCTCAGTGTAGCCCAAGATGC.

## 2.8. Statistics

Data are expressed as the mean  $\pm$  standard deviation. For statistical analysis, we used *Student's t-test* with a two-tailed distribution, and two-sample equal variance (homoscedastic), for significance.  $p < 0.05$  was considered significant.

## 3. Results

### 3.1. *Sostdc1* deletion decreases trabecular and increases cortical bone volume

*Sostdc1*<sup>-/-</sup> mice displayed 31% lower trabecular bone volume fraction (BV/TV) in the distal femoral metaphysis and 35% less in the L4 vertebral body compared to controls ( $p < 0.05$ ). Connectivity density ( $p < 0.005$ ), and trabecular number ( $p < 0.0005$ ) were also reduced 30% and 18%, in the distal femur, respectively. Trabecular separation ( $p < 0.005$ ) was increased 28% in the femur and 31% in L4, consistent with a lower trabecular bone volume phenotype. However, bone tissue BMD (mg HA/cm<sup>3</sup>) was increased in the cortical bone, relative to *WT* ( $p = 0.05$ ) (Table 1). In contrast to the trabecular compartments, the cortical compartment indicated that the bones (total area, TA) were larger (TA 2.02 vs 2.35,  $p < 0.05$ ). The cortical

total area was increased by 16%, and the marrow area was enlarged by 21% ( $p < 0.01$ ) (Table 1). These data show that *Sostdc1* modulates bone metabolism differently in the cortical than in the trabecular compartments of bone.

### 3.2. *Sostdc1*<sup>-/-</sup> mice exhibit enhanced cortical bone formation

Histomorphometric analysis of mid-femur regions of 5.5 month old mice on the periosteal and endocortical surfaces indicated enhanced bone formation in *Sostdc1*<sup>-/-</sup> mice, with a significant increase in mineralized surface (MS/BS) and 78% increase on the periosteal surface ( $p < 0.035$ ). An 8% increase on the endocortical surface was also observed, but this change was not statistically significant. We also observed a 30% increase in the bone formation rate (BFS/BS) on the periosteal surface of *Sostdc1*<sup>-/-</sup> mice compared to *WT* controls, indicating significantly more active bone formation on the periosteal surface compared to the endocortical surface. There was a significant 32% decrease in BFR/BS ( $p = 0.0497$ ) and 42% decrease in mineral apposition rate (MAR) ( $p < 0.00013$ ) on the endocortical surface and no change on the periosteal surface in *Sostdc1*<sup>-/-</sup> mice compared to *WT* controls (Table 2). The decreased change in both MAR and BFR/BS suggests that the endocortical region of *Sostdc1*<sup>-/-</sup> femora has a reduced remodeling rate, which, combined with the more active bone formation rate on the periosteal surface, contributes to the high bone mass phenotype and larger bone morphology observed in the cortices of *Sostdc1*<sup>-/-</sup> femora (Table 2). In addition, we compared intact mid-diaphyseal  $\mu$ CT data at 12 weeks of age data (Sup. Fig. 1C). Only the marrow area was significantly larger in the *Sostdc1*<sup>-/-</sup> femora at this time point. Cortical reconstruction images do not indicate cortical thinning or enlargement indicative of premature aging in *Sostdc1*<sup>-/-</sup> mice (Sup. Fig. 1A,B). These data show that lack of *Sostdc1* promotes periosteal cortical bone formation, suggesting that *Sostdc1*, similarly to *Sost*, acts as a negative regulator of bone formation, although its function is regionally restricted to the diaphysis due to its periosteal expression [26].

We examined osteoclast differentiation in these mice as well, and scored hematopoietic progenitors by flow cytometry (Sup. Fig. 2A, B). We found no significant differences ( $p < 0.05$ ) in numbers of osteoclast progenitors of the types indicated. In addition, TRAP stains on 12-week old mice (Sup. Fig. 2C) indicate that there are no gross differences in mature osteoclast number. These data corroborate evidence by histomorphometry that do not suggest increased resorption in *Sostdc1*<sup>-/-</sup> compared to mice *WT*.

### 3.3. *Sostdc1*-positive cells participate in early fracture repair

*Sostdc1* expression *in vivo* was examined by tracking the *LacZ* reporter from the *Sostdc1* knock-in allele [8]. In neonatal *Sostdc1*<sup>+/-</sup> mice, *LacZ* expression was observed in tissues adjacent or near the bone, including the adipose and periarticular cartilage (Sup. Fig. 3A-E). We also noted *LacZ* expression in the proliferating chondrocytes of the neonatal epiphysis [12] (Sup. Fig. 3A, E); this expression did not persist into the adult growth plate or articular cartilage (Sup. Fig. 3F, J). In intact adult *Sostdc1*<sup>+/-</sup> femora, *LacZ* was observed in the periosteum, muscle, and vasculature (Sup. Fig. 3F-J).

To examine the functional consequence of losing *Sostdc1* expression in adult mice, we performed transverse femoral fractures in *Sostdc1*<sup>-/-</sup> mice, and tracked the *Sostdc1*-deficient



cells using *LacZ*. In unfractured *Sostdc1*<sup>-/-</sup> femora, *LacZ* was expressed in the same pattern as the *LacZ* determined for *Sostdc1*<sup>+/-</sup> femora, primarily in the periosteum (Fig. 1A), muscle and vasculature (Fig. 1E). At 3 days post fracture (D3), the rapidly expanded periosteum contained primarily *LacZ*-positive cells (Fig. 1B). Furthermore, *LacZ*-positive cells appeared to migrate from the interstitial space of the adjacent injured skeletal muscle and the vasculature (Fig. 1B-C, F-G, I-J). The elevated density of *LacZ*-positive cells was confined to the fractured limb (B, F, I), in regions adjacent to the injury site, and was not observed in the contralateral limb (Fig. 1A, E). We found no expression *LacZ*-positive cells in the chondrocytes of uninjured animals, including in the growth plate (Sup. Fig. 4A). However, patellar chondrocytes distal to the injury site on the broken limb activated *LacZ* expression shortly after injury (Sup. Fig. 4B). This suggests that *Sostdc1* transcriptional activation is mediated locally by the traumatic injury.

At 7 days post injury (D7) many *LacZ*-positive cells remained in the periphery of the developing callus (Fig. 1C, G, J). Migratory cells remained present in the soft tissue surrounding the bone injury (Fig. 1G, J). Fewer *LacZ*-positive cells were observed in the vasculature (Fig. 1J). By 10 days post fracture (D10), weak *LacZ* expression emerged in the developing cartilage callus (Fig. 1K), and *LacZ*-positive cells had embedded into the newly formed bone surface (Fig. 1D, K; arrows). Histologically, we observed bone formation as cells with mesenchymal morphology, yet surrounded by abundant matrix, increasing their cell-to-cell spacing (Fig. 1D, K), in contrast to the tightly packed mesenchymal cells observed in the D3 and D7 callus (Fig. 1B-C; F-G, I-J). At this stage of repair, *LacZ* expression decreased in the fracture callus and in the surrounding tissues. *LacZ* expression primarily marked the boundary between muscle and bone at the edge of the callus and the soft tissue near the skin (Fig. 1D, H, K). Immature chondrocytes near the callus edge continued to show weak *LacZ* expression, yet no *LacZ* expression was observed in the hypertrophic chondrocytes of the callus, consistent with the lack of expression in uninjured adult bones (Sup. Fig. 4C, D).

*LacZ*-positive cells were confined to the periosteal and soft tissue compartments of the *Sostdc1*<sup>-/-</sup> limb, at all time points examined. No *LacZ*-positive cells were found on the endosteal surfaces or in the marrow cavity of contralateral, uninjured limbs, nor was *LacZ* activated in these regions of the injured limb, in response to injury. No *LacZ*-positive cells were seen in the metaphyseal trabecular niche of the uninjured bones, or in the injured bones in response to injury at any time point examined (Supporting Fig. 3A, D, F). During fracture repair, we conclude that *LacZ*-positive cells in *Sostdc1*<sup>-/-</sup> injured femora, and hence *Sostdc1*-positive cells in injured *WT* femora, appear to migrate from the soft tissues surrounding the injury, including periosteum, vasculature, and/or muscle, and participate in early fracture repair events. Participation of these *LacZ*-positive cells diminished at later milestones of healing, and was not present in the mature cartilage or in bone cells, suggesting that *Sostdc1* may mark a population of periosteal osteochondral progenitor cells needed for fracture repair.



### 3.4. Fracture healing program is altered in *Sostdc1*<sup>-/-</sup> mice

Histological analysis of *Sostdc1*<sup>-/-</sup> calluses revealed several differences between *Sostdc1*<sup>-/-</sup> mice and *WT* or *Sostdc1*<sup>+/-</sup> controls throughout the 28-day fracture healing interval examined (Fig. 2). Starting at D3, *Sostdc1*<sup>-/-</sup> mice had an enhanced periosteal reaction, as characterized by a thicker layer of undifferentiated cells in the periosteal areas adjacent to the injury (Fig. 2A, F). By D7, the cartilage callus was larger in *Sostdc1*<sup>-/-</sup> mice and intramembranous bone formation was more robust (Fig. 2B), with pronounced vascular invasion, as indicated by the presence of red blood cells in vessels (Fig. 2B; arrow). In contrast, *WT* calluses displayed insignificant intramembranous bone formation or neovascularization (Fig. 2G). At D14, while vascular invasion was occurring only at the periphery of the cartilage callus of *WT* animals (Fig. 2H), *Sostdc1*<sup>-/-</sup> mice had evident neovasculature deeper within the interior of the callus (Fig. 2C). By D21, the calluses of each genotype looked distinctly different, with *Sostdc1*<sup>-/-</sup> calluses showing a thick cortical shell surrounding the callus, very little woven bone in the interior of the callus, and original cortical bone that was remodeling, compared to *WT* (Fig. 2D, I; arrows). These mature calluses in *Sostdc1*<sup>-/-</sup> mice showed no evidence of persistent cartilage in the callus relative to matched controls. These data suggest that the absence of *Sostdc1* accelerates and/or enhances intramembranous bone formation and neovascularization in the callus.

### 3.5. *Sostdc1*<sup>-/-</sup> mice have larger, more mineralized fracture calluses with normal mechanical strength

*Sostdc1*<sup>-/-</sup> fractured limbs had a significantly increased callus size (60%,  $p < 0.05$ ) and increased apparent bone mineral density (3%;  $p < 0.0005$ ) at D28, compared to *WT* calluses (Fig. 2E, J; Table 3). While bone volume was increased ( $p < 0.01$ ), BV/TV was increased by 36%, but this value was not significantly different between *Sostdc1*<sup>-/-</sup> and *WT* controls, due to large animal to animal variation. Mechanical testing of intact bones and calluses revealed that *Sostdc1*<sup>-/-</sup> femora and calluses were not mechanically different from *WT* controls (Table 3), as determined by torsional stiffness, ultimate torque at failure and rotation at ultimate failure quantification. Larger calluses (Fig. 2E, J), with an increased mineral content indicated they were structurally mature. These data suggests that *Sostdc1*<sup>-/-</sup> fractured femora have an expedited healing program compared to *WT* controls, and that the healed calluses may yield stronger repaired bones.

### 3.6. *Sostdc1* marks a population of osteochondral progenitor cells

Since *Sostdc1*-positive cells display migratory, proliferative, and differentiation capabilities consistent with those of mesenchymal stem cells (MSCs), we next examined co-localization of stem cell markers nestin and alpha smooth muscle actin ( $\alpha$ -SMA) with *LacZ* as a surrogate of *Sostdc1* expression, in D3 and D7 calluses (Fig. 3). We compared *LacZ* expression in *Sostdc1*<sup>-/-</sup> and *Sostdc1*<sup>+/-</sup> calluses using an antibody specific for its gene product,  $\beta$ -galactosidase. Nestin is a mesenchymal cell marker used in flow cytometry to identify mesenchymal stem cell populations [27] and  $\alpha$ -SMA marks progenitor cells that can differentiate into chondrocytes and osteoblasts [2].  $\beta$ -galactosidase antibody stain (Fig. 3G-R; red) closely resembled the  $\beta$ -galactosidase enzymatic activity (Fig. 3A-C). While nestin and  $\beta$ -galactosidase co-localized in only a few periosteal cells in *Sostdc1*<sup>-/-</sup> intact

femora (Fig. 3G, J), at D3 there was a discernable increase in the population of nestin - LacZ double positive cells, in the expanded periosteal region of *Sostdc1*<sup>-/-</sup> fractures (Fig. 3H, K). By D7, a large fraction of the *Sostdc1*<sup>-/-</sup> callus harbored nestin - LacZ double positive cells (Fig. 3I), and now a smaller such population emerged in the *Sostdc1*<sup>+/-</sup> callus (Fig. 3L), suggesting that *Sostdc1* may mark a unique population of periosteal derived stem cells. In contrast, at D3,  $\alpha$ -SMA - LacZ marked mostly cells resembling well-developed blood vessels at the muscle-bone interface of *Sostdc1*<sup>-/-</sup> calluses (Fig. 3N, Q), with insignificant evidence of neovascularization at this time-point in *Sostdc1*<sup>+/-</sup> controls. By D7, the population of  $\alpha$ -SMA - LacZ-positive increased in *Sostdc1*<sup>-/-</sup> calluses without a correspondent increase in the *Sostdc1*<sup>+/-</sup> control calluses (Fig. 3O, R). The overlapping expression of  $\beta$ -galactosidase with either nestin or  $\alpha$ -SMA initiated at ~D3 and showed similar elevated levels near the site of injury at D7, suggesting that they mark a small population of rapidly dividing cells that are migrating from the periosteum and/or vasculature into the injured site.

Quantitative analysis of nestin and  $\alpha$ -SMA-positive cells, revealed a significant increase in the number of stem cell marker positive cells in *Sostdc1*<sup>-/-</sup> mice, compared to controls (Fig. 3S, T) which suggests that lack of *Sostdc1* promotes or accelerates progenitor or stem cell response to injury and supports a role for *Sostdc1* in stem cell maintenance. Protein expression of Osterix (Sp7/Osx), a transcription factor essential for the differentiation of pre-osteoblasts into mature osteoblasts [28], was similarly analyzed. Significant differences were observed in intact femora, where *Sostdc1*<sup>-/-</sup> periosteal cells expressed higher levels of Osx than controls (Fig. 4A, D). At D3, the periosteal region closest to the cortical bone showed increased expression of Osx in *Sostdc1*<sup>-/-</sup> mice (Fig. 4B, E). Significantly more Osx-positive cells remained near the periosteal surface of *Sostdc1*<sup>-/-</sup> D7 calluses, compared to *Sostdc1*<sup>+/-</sup> controls (Fig. 4C, F, G) suggesting that lack of *Sostdc1* promotes differentiation towards the osteoblast lineage.

### 3.7. *Sostdc1*<sup>-/-</sup> hastens the expansion and differentiation of mesenchymal cells during fracture repair

Using cell surface signatures established for mesenchymal stem cells (MSC) [25] and mature osteoblasts (OB) [25] we quantified MSC and OB populations in *Sostdc1*<sup>-/-</sup> and *WT* femora in intact contralateral limbs and 5, 6, 7 days post fracture. No significant differences were observed in the frequency of MSCs or OBs in *Sostdc1*<sup>-/-</sup> and *WT* intact femora or at D7 (Table 4). At D5, while the MSC and OB populations remained at baseline levels in *WT* femora, the *Sostdc1*<sup>-/-</sup> injured bones had significantly more MSCs (>2-fold; p<0.0105) and OBs (>3-fold; p<0.00246). At D6, the *WT* MSC population reached 8-fold above baseline; whereas the MSC population in the *Sostdc1*<sup>-/-</sup> was significantly lower than *WT* (Table 4, Fig. 5B). The *Sostdc1*<sup>-/-</sup> OB population tended to outpace the magnitude observed in the *WT*, at D6, but was stabilized between the genotypes by D7, with significant differences only observed at D5 (Table 4). We also quantified the populations of endothelial cells and found no significant differences between *WT* and *Sostdc1*<sup>-/-</sup>, at all time points examined. Furthermore, we found *LacZ* expression only within MSCs, consistent with *Sostdc1* marking a subpopulation of osteochondral progenitor cells (Fig. 5A).

We next questioned whether loss of *Sostdc1* enhances fracture repair by enhancing the differentiation of MSCs in a cell autonomous fashion, or whether the enhanced fracture repair resulted from increased number of both MSCs and OBs in *Sostdc1*<sup>-/-</sup> mice. To discriminate between the two potential scenarios, we plotted frequency of each cell type as a function of days *post* fracture. The resulting curve for MSCs exhibited a left shift in *Sostdc1*<sup>-/-</sup> compared to *WT* mice (Fig. 5B), as did the curve of OBs (Fig. 5C), however, computing the area under the curve generated highly similar values for *Sostdc1*<sup>-/-</sup> and *WT* MSC profiles (Table 4). This temporal shift in MSC expansion can also be visually observed in the nestin and  $\alpha$ -SMA immunostains where the double positive population is always higher in the *Sostdc1*<sup>-/-</sup> (Fig. 3H, I, K, L, N, O, R) than in the *Sostdc1*<sup>+/-</sup> calluses. However, the immunostain quantification indicates both significantly more nestin<sup>+</sup> cells and  $\alpha$ -SMA<sup>+</sup> cells (indicators of stem cells) in *Sostdc1*<sup>-/-</sup> at D7 compared to *Sostdc1*<sup>+/-</sup> (Fig. 3). This difference may be due to the use of whole broken bones for the flow cytometry analysis, compared to fracture-callus-only for immunostain quantification. In addition, the immunostain quantification used single markers, and both nestin and  $\alpha$ -SMA may also indicate the presence of endothelial cells [29] while the cell surface markers define endothelial cells as a separate population, and could contribute to the differences seen at D7 between the two analyses. The temporal shift in MSCs populating the callus is consistent with a rapid shift in cellular identity which contributes to the accelerated differentiation into OB in the *Sostdc1*<sup>-/-</sup> calluses (see also Fig. 4) and is reconciled as a greater area under the curve for *Sostdc1*<sup>-/-</sup> OBs (Fig. 5, Table 4). As later time points did not have osteoblast quantification by flow cytometry, it is not possible to determine whether there is a greater absolute number of osteoblasts throughout fracture healing in *Sostdc1*<sup>-/-</sup> compared to *WT*, or if there is simply an early shift toward differentiation in the *Sostdc1*<sup>-/-</sup> calluses. However, at late time points during repair, *Sostdc1*<sup>-/-</sup> mice show enhanced callus volume, BV, and mineral density (Table 3) suggesting that increased osteoblast differentiation, or relative number early in repair, translates to more bone formation (Table 3).

### 3.8. Loss of *Sostdc1* activates Wnt signaling during fracture repair

*Sostdc1* had been described as both a BMP and a Wnt antagonist [16], and we have previously shown that *Sostdc1* does not behave as a canonical Wnt antagonist in the context of limb development [12]. We examined the expression pattern of activated  $\beta$ -catenin in the fracture callus at D3 and D7 to determine whether *Sostdc1* behaves similarly in the context of fracture repair. In contrast to our limb analyses, we found dramatically increased levels of activated  $\beta$ -catenin in *Sostdc1*<sup>-/-</sup> mice, compared to controls (Fig. 6). In unbroken bones, we found increased signal at the periosteal surface and in the metaphyseal niche of *Sostdc1*<sup>-/-</sup> mice, compared to controls (Fig. 6A, B, F, G). At D3 post-fracture, higher levels of activated  $\beta$ -catenin were observed in the periosteum as well as in the cortical bone of *Sostdc1*<sup>-/-</sup> femora (Fig. 6C, H). By D7, increased levels of activated  $\beta$ -catenin were observed in the periphery of the developing cartilaginous callus (excluding chondrocytes), and the expression intensified in regions resembling blood vessels in the callus (Fig 6D, I; brackets/arrows). Furthermore, the developing neovascular network in the callus consisted of larger diameter vessels compared to controls. Woven bone present in the marrow space of D7 injured femurs also contained elevated levels of activated  $\beta$ -catenin in *Sostdc1*<sup>-/-</sup> mice (Fig. 6E, J). The increase in activated  $\beta$ -catenin levels in the metaphysis and cortical bone

suggests that *Sostdc1* affects canonical Wnt signaling in a non-cell-autonomous manner, and it implies that the increase in cortical bone is due to elevated Wnt signaling.

#### 4. Discussion

*Sost* is a potent negative regulator of bone formation and *Sost* deficiency contributes to high bone mass and enhanced fracture healing phenotypes; yet its paralog *Sostdc1*, which is expressed in the periosteum, has not yet been examined for its potential contribution to bone repair despite the established role of periosteal cells in fracture healing [4, 30]. Here we report that global loss of *Sostdc1* results in a complex skeletal phenotype characterized by an increase in femoral cortical bone structure and BMD, but with reduced trabecular bone mass. Since periosteal osteoblasts are responsible for outward expansion of long bones, our results suggest that lack of *Sostdc1* increases the osteoblast activity locally in the periosteum, resulting in larger, thicker bone cortices. The increased moment of inertia (pMOI) in *Sostdc1*<sup>-/-</sup> femurs suggested that the increase in periosteal activity among *Sostdc1*<sup>-/-</sup> mice might translate into improved bending properties for the diaphysis. These findings are consistent with results published by He *et al.*, who correlated a polymorphism in *Sostdc1* with low lumbar BMD but not with femoral neck or total hip BMD, in Chinese women [31]. Since lumbar vertebrae are primarily composed of trabecular bone, this human association study suggests that mutations that interfere with *Sostdc1* function may negatively influence trabecular BMD to a greater extent than cortical BMD.

Previous studies have shown that both *Sostdc1* and *Sost* inhibit Wnt signaling by binding to multiple Lrp co-receptors (Lrp1, Lrp4, Lrp5 and Lrp6) [32–34], and that *Sost* primarily functions in a cell non-autonomous manner wherein it is secreted by osteocytes and binds to receptors on the osteoblast surface. The loss of *Sost* results in a robust response in trabecular bone, contributing to strengthening and replenishment of trabeculae in the case of osteoporosis. Loss of *Sost*, as with Sclerostin-neutralizing antibody treatment, also directs fracture calluses and stem cells toward enhanced bone formation, although it is not yet clear by what mechanism [35, 36]. Thus, we speculated that due to its expression in periosteum, *Sostdc1* may exert its effects on periosteal osteoblasts in a similar fashion, where it is secreted by periosteal cells and binds to Lrp co-receptors on the neighboring osteoblasts residing on the periosteal bone surface. Since osteoblasts residing on the periosteal surface of cortical bones are likely to be exposed to both *Sostdc1* from the periosteum and to *Sost* from the underlying osteocytes, the periosteal osteoblasts may be more sensitive to levels of Wnt antagonists, and therefore may be more likely to upregulate  $\beta$ -catenin-dependent Wnt signaling in the absence of *Sostdc1* than osteoblasts residing on the trabecular surfaces. Immunohistological analysis of activated  $\beta$ -catenin expression supports this hypothesis, where we observe greater levels of activated  $\beta$ -catenin on the periosteal surface of *Sostdc1*<sup>-/-</sup> than in *Sostdc1*<sup>+/-</sup> controls (Fig. 6A, F).

Since the cambium layer of the periosteum is also a major source of osteoblast and chondrocyte progenitors during fracture healing, we also examined whether *Sostdc1*-deficient periosteal cells interfere with normal fracture healing. After injury, a typical periosteal thickening was observed accompanied by a rapid expansion of *Sostdc1-LacZ* positive cells with mesenchymal morphology that populated most of the callus forming

region at D3. Beyond D7, these *LacZ* positive cells became restricted to regions closer to the periosteum, suggesting that the *Sostdc1*-expressing cells rapidly expand during periosteal reaction and are subsequently recruited into the fracture site where they participate in the soft callus formation. FACS analysis of MSCs in combination with histological staining with stem cell markers nestin and  $\alpha$ -SMA indicate that *Sostdc1*-positive cells in the early fracture callus mark a subpopulation of multipotent mesenchymal stem cells that migrate into the callus from the periosteum. The behavior of *Sostdc1*-positive cells is similar to osteochondroprogenitor cells in the periosteum that, using lineage tracing, make a major contribution to the soft callus [30]. The role of *Sostdc1* as a WNT antagonist, and the known role of WNT/ $\beta$ -catenin signaling to promote osteogenic<sup>[37]</sup> and chondrogenic [38, 39] differentiation and maturation, suggests that *Sostdc1* may act as the rate-limiting inhibitor of the differentiation of pluripotent periosteal cells during fracture repair. Indeed, we observe a temporal shift in the frequency of MSC and OB subpopulations during fracture repair in *Sostdc1*<sup>-/-</sup> mice, as well as greater area-under-curve of OBs, but not of MSCs, indicating more rapid activation of migration, proliferation and differentiation of MSCs and OBs, and further supporting the role of *Sostdc1* as an osteochondral progenitor gatekeeper. Further exploration of *Sostdc1* may define it as a morphogen that functions to maintain stem cells in a progenitor state [40].

## 5. Conclusion

This work describes *Sostdc1* activity in a new context, highlighting its potential role in the metabolism and repair of the skeleton. In addition, for the first time we have linked *Sostdc1* to the behavior of mesenchymal stem cells, which is consistent with, and mechanistically may explain *Sostdc1*-related phenotypes noted by other published studies, such as in cancer prognosis, tooth development, kidney injury resistance, and diet-induced obesity resistance. We have shown that *Sostdc1*<sup>LacZ</sup> is expressed in *Sostdc1*<sup>-/-</sup> MSCs, therefore, *Sostdc1* expression marks a subpopulation of osteochondral progenitor cells, and have shown that stem cell response is enhanced in the absence of *Sostdc1* after injury, accelerating bone repair. We have demonstrated that *Sostdc1* is important for trabecular bone maintenance, bone formation, early fracture repair events, and the lack of *Sostdc1* influences mesenchymal stem cell behavior in response to injury, *in vivo*. Future work may show a synergy between the loss of *Sost* and *Sostdc1* to combine enhanced trabecular bone and enhanced cortical bone in the treatment of fractures and osteoporosis.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

We would like to thank the National Institutes of Health (NIH) Knock-Out Mouse Program (KOMP) and Regeneron for providing the *Sost* and *Sostdc1* knockout mice. We are also grateful to David Gravano for his assistance with FACS analysis. NMC, CSY, DKM and GGL were supported in part by NIH grant DK075730. NMC and GGL were also supported in part by LLNL LDRD ER (11-ERD-060). This work was performed under the auspices of the U.S. Department of Energy by Lawrence Livermore National Laboratory under Contract DE-AC52-07NA27344.

## References

1. Colnot C. Cell sources for bone tissue engineering: insights from basic science. *Tissue Eng Part B Rev.* 2011; 17:449–57. [PubMed: 21902612]
2. Grcevic D, Pejda S, Matthews BG, Repic D, Wang L, Li H, Kronenberg MS, Jiang X, Maye P, Adams DJ, Rowe DW, Aguila HL, Kalajzic I. In vivo fate mapping identifies mesenchymal progenitor cells. *Stem Cells.* 2012; 30:187–96. [PubMed: 22083974]
3. Matthews BG, Grcevic D, Wang L, Hagiwara Y, Roguljic H, Joshi P, Shin DG, Adams DJ, Kalajzic I. Analysis of alphaSMA-labeled progenitor cell commitment identifies notch signaling as an important pathway in fracture healing. *J Bone Miner Res.* 2014; 29:1283–94. [PubMed: 24190076]
4. Colnot C. Skeletal cell fate decisions within periosteum and bone marrow during bone regeneration. *J Bone Miner Res.* 2009; 24:274–82. [PubMed: 18847330]
5. Maes C, Kobayashi T, Selig MK, Torrekens S, Roth SI, Mackem S, Carmeliet G, Kronenberg HM. Osteoblast precursors, but not mature osteoblasts, move into developing and fractured bones along with invading blood vessels. *Dev Cell.* 2010; 19:329–44. [PubMed: 20708594]
6. Laurikkala J, Kassai Y, Pakkasjarvi L, Thesleff I, Itoh N. Identification of a secreted BMP antagonist, ectodin, integrating BMP, FGF, and SHH signals from the tooth enamel knot. *Dev Biol.* 2003; 264:91–105. [PubMed: 14623234]
7. Yanagita M, Okuda T, Endo S, Tanaka M, Takahashi K, Sugiyama F, Kunita S, Takahashi S, Fukatsu A, Yanagisawa M, Kita T, Sakurai T. Uterine sensitization-associated gene-1 (USAG-1), a novel BMP antagonist expressed in the kidney, accelerates tubular injury. *J Clin Invest.* 2006; 116:70–9. [PubMed: 16341262]
8. Tanaka M, Endo S, Okuda T, Economides AN, Valenzuela DM, Murphy AJ, Robertson E, Sakurai T, Fukatsu A, Yancopoulos GD, Kita T, Yanagita M. Expression of BMP-7 and USAG-1 (a BMP antagonist) in kidney development and injury. *Kidney Int.* 2008; 73:181–91. [PubMed: 17943079]
9. Clausen KA, Blish KR, Birse CE, Triplette MA, Kute TE, Russell GB, D'Agostino RB Jr, Miller LD, Torti FM, Torti SV. SOSTDC1 differentially modulates Smad and beta-catenin activation and is down-regulated in breast cancer. *Breast Cancer Res Treat.* 2011; 129:737–46. [PubMed: 21113658]
10. Ahn Y, Sims C, Logue JM, Weatherbee SD, Krumlauf R. Lrp4 and Wise interplay controls the formation and patterning of mammary and other skin appendage placodes by modulating Wnt signaling. *Development.* 2013; 140:583–93. [PubMed: 23293290]
11. Simmons DG, Kennedy TG. Uterine sensitization-associated gene-1: a novel gene induced within the rat endometrium at the time of uterine receptivity/sensitization for the decidual cell reaction. *Biol Reprod.* 2002; 67:1638–45. [PubMed: 12390898]
12. Collette NM, Yee C, Muruges D, Sebastian A, Taher L, Gale NW, Economides AN, Harland RM, Loots GG. Sost and its paralog Sostdc1 coordinate digit number in a Gli3-dependent manner. *Dev Biol.* 2013
13. Itasaki N, Jones CM, Mercurio S, Rowe A, Domingos PM, Smith JC, Krumlauf R. Wise, a context-dependent activator and inhibitor of Wnt signalling. *Development.* 2003; 130:4295–305. [PubMed: 12900447]
14. Ohazama A, Johnson EB, Ota MS, Choi HY, Porntaveetus T, Oommen S, Itoh N, Eto K, Gritli-Linde A, Herz J, Sharpe PT. Lrp4 modulates extracellular integration of cell signaling pathways in development. *PLoS One.* 2008; 3:e4092. [PubMed: 19116665]
15. Ahn Y, Sanderson BW, Klein OD, Krumlauf R. Inhibition of Wnt signaling by Wise (Sostdc1) and negative feedback from Shh controls tooth number and patterning. *Development.* 2010; 137:3221–31. [PubMed: 20724449]
16. Lintern KB, Guidato S, Rowe A, Saldanha JW, Itasaki N. Characterization of wise protein and its molecular mechanism to interact with both Wnt and BMP signals. *J Biol Chem.* 2009; 284:23159–68. [PubMed: 19553665]
17. van Dinther M, Zhang J, Weidauer SE, Boschert V, Muth EM, Knappik A, de Gorter DJ, van Kasteren PB, Frisch C, Mueller TD, ten Dijke P. Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling. *PLoS One.* 2013; 8:e62295. [PubMed: 23638027]




18. Collette NM, Genetos DC, Muruges D, Harland RM, Loots GG. Genetic evidence that SOST inhibits WNT signaling in the limb. *Dev Biol.* 2010; 342:169–79. [PubMed: 20359476]
19. Cho SW, Kwak S, Woolley TE, Lee MJ, Kim EJ, Baker RE, Kim HJ, Shin JS, Tickle C, Maini PK, Jung HS. Interactions between Shh, Sostdc1 and Wnt signaling and a new feedback loop for spatial patterning of the teeth. *Development.* 2011; 138:1807–16. [PubMed: 21447550]
20. Bonnarens F, Einhorn TA. Production of a standard closed fracture in laboratory animal bone. *J Orthop Res.* 1984; 2:97–101. [PubMed: 6491805]
21. Lobe CG, Koop KE, Kreppner W, Lomeli H, Gertsenstein M, Nagy A. Z/AP, a double reporter for cre-mediated recombination. *Dev Biol.* 1999; 208:281–92. [PubMed: 10191045]
22. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. *J Bone Miner Res.* 2010; 25:1468–86. [PubMed: 20533309]
23. Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR, Parfitt AM. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. *J Bone Miner Res.* 2013; 28:2–17. [PubMed: 23197339]
24. Kedlaya R, Veera S, Horan DJ, Moss RE, Ayturk UM, Jacobsen CM, Bowen ME, Paszty C, Warman ML, Robling AG. Sclerostin inhibition reverses skeletal fragility in an *Lrp5*-deficient mouse model of OPG syndrome. *Sci Transl Med.* 2013; 5:211ra158.
25. Schepers K, Hsiao EC, Garg T, Scott MJ, Passegue E. Activated Gs signaling in osteoblastic cells alters the hematopoietic stem cell niche in mice. *Blood.* 2012; 120:3425–35. [PubMed: 22859604]
26. Collette NM, Yee CS, Muruges D, Sebastian A, Taher L, Gale NW, Economides AN, Harland RM, Loots GG. Sost and its paralog Sostdc1 coordinate digit number in a Gli3-dependent manner. *Dev Biol.* 2013; 383:90–105. [PubMed: 23994639]
27. Birbrair A, Wang ZM, Messi ML, Enikolopov GN, Delbono O. Nestin-GFP transgene reveals neural precursor cells in adult skeletal muscle. *PLoS One.* 2011; 6:e16816. [PubMed: 21304812]
28. Baek WY, Lee MA, Jung JW, Kim SY, Akiyama H, de Crombrughe B, Kim JE. Positive regulation of adult bone formation by osteoblast-specific transcription factor osterix. *J Bone Miner Res.* 2009; 24:1055–65. [PubMed: 19113927]
29. Lama G, Mangiola A, Proietti G, Colabianchi A, Angelucci C, D'Alessio A, De Bonis P, Geloso MC, Lauriola L, Binda E, Biamonte F, Giuffrida MG, Vescovi A, Sica G. Progenitor/Stem Cell Markers in Brain Adjacent to Glioblastoma: GD3 Ganglioside and NG2 Proteoglycan Expression. *J Neuropathol Exp Neurol.* 2016
30. Muraio H, Yamamoto K, Matsuda S, Akiyama H. Periosteal cells are a major source of soft callus in bone fracture. *J Bone Miner Metab.* 2013; 31:390–8. [PubMed: 23475152]
31. He JW, Yue H, Hu WW, Hu YQ, Zhang ZL. Contribution of the sclerostin domain-containing protein 1 (SOSTDC1) gene to normal variation of peak bone mineral density in Chinese women and men. *J Bone Miner Metab.* 2011; 29:571–81. [PubMed: 21221677]
32. Ellies DL, Viviano B, McCarthy J, Rey JP, Itasaki N, Saunders S, Krumlauf R. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. *J Bone Miner Res.* 2006; 21:1738–49. [PubMed: 17002572]
33. Semenov M, Tamai K, He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. *J Biol Chem.* 2005; 280:26770–5. [PubMed: 15908424]
34. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. *J Biol Chem.* 2005; 280:19883–7. [PubMed: 15778503]
35. Yee CS, Xie L, Hatsell S, Hum N, Muruges D, Economides AN, Loots GG, Collette NM. Sclerostin Antibody Treatment Improves Fracture Outcomes in a Type I Diabetic Mouse Model. *Bone.* 2015
36. Liu Y, Rui Y, Cheng TY, Huang S, Xu L, Meng F, Lee WY, Zhang T, Li N, Li C, Ke H, Li G. Effects of Sclerostin Antibody on the Healing of Femoral Fractures in Ovariectomised Rats. *Calcif Tissue Int.* 2016; 98:263–74. [PubMed: 26603303]
37. Friedman MS, Oyserman SM, Hankenson KD. Wnt11 promotes osteoblast maturation and mineralization through R-spondin 2. *J Biol Chem.* 2009; 284:14117–25. [PubMed: 19213727]



38. Liu S, Zhang E, Yang M, Lu L. Overexpression of Wnt11 promotes chondrogenic differentiation of bone marrow-derived mesenchymal stem cells in synergism with TGF-beta. *Mol Cell Biochem.* 2014; 390:123–31. [PubMed: 24474615]
39. Yano F, Kugimiya F, Ohba S, Ikeda T, Chikuda H, Ogasawara T, Ogata N, Takato T, Nakamura K, Kawaguchi H, Chung UI. The canonical Wnt signaling pathway promotes chondrocyte differentiation in a Sox9-dependent manner. *Biochem Biophys Res Commun.* 2005; 333:1300–8. [PubMed: 15979579]
40. Boland GM, Perkins G, Hall DJ, Tuan RS. Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells. *J Cell Biochem.* 2004; 93:1210–30. [PubMed: 15486964]


**Highlights**

- *Sostdc1* is expressed in the periosteum
- *Sostdc1*<sup>-/-</sup> mice exhibit increased cortical bone volume caused by an increase in bone formation
- *Sostdc1*-positive periosteal cells participate in early fracture repair
- *Sostdc1*<sup>-/-</sup> mice have larger, more mineralized fracture calluses with normal mechanical strength
- *Sostdc1* marks a population of osteochondral progenitor cells
- Lack of *Sostdc1* elevates Wnt signaling in the fracture callus



**Fig. 1.** Histological characterization of early time points in fracture repair of *Sostdc1*<sup>-/-</sup> mice shows *LacZ* expression [as a surrogate for *Sostdc1* expression] in and around the early fracture callus. Schematics are shown for unfractured, and the fractured femora at 3, 7, and 10 days post-fracture; boxes within this schematic indicate regions visualized for each time point. Deep orange- soft tissue outside bone; blue- periosteum and undifferentiated cells; red- clot or vasculature; light orange- cartilage callus; yellow- bone. Control unfractured *Sost*<sup>-/-</sup> limb (A, E) shows *LacZ* expression in the periosteum (A), and in intermittent cells in muscle tissue and peripheral vascular tissue (E). Images taken at D3 post-fracture show *LacZ* expression in the expanded periosteum (B) and evidence of cell migration into the callus (I). Cells within muscle and periosteum distal to the fracture site are also strongly *LacZ*-positive at this early time point (F). In nearby muscle, *LacZ*-positive cells appear to occupy the


interstitial space, and appear to migrate out from the vasculature (B, F, I). At D7 *LacZ* expression begins to fade (C, G, J). The outside of the callus is marked by *LacZ*-positive cells (C). Undifferentiated cells continue to be found near the periphery of the callus in undefined tissue (G). At the edges of the muscle, positive cells are located in distinct cluster near connective tissue surrounding muscle bundles (G, J). By D10 post-fracture, *LacZ* expression is reduced both in terms of numbers and intensity (D, H, K). Newly formed periosteum, embedding osteoblasts, and nearby developing muscle show cells around the boundaries that express *LacZ* (arrows) (D, H). Undifferentiated cells near the periphery of the callus retain *LacZ* expression (K). *LacZ* expression is also found in the healing muscle tissue outside the callus proper (D). Images are shown at 40× magnification. m muscle; v blood vessel; p periosteum; pa patella; cb cortical bone; hc hypertrophic chondrocytes; bm bone marrow; b newly formed bone; ch chondrocytes.



**Fig. 2.**

Fracture callus is larger at 28 days post-fracture in *Sostdc1*<sup>-/-</sup> mice and H&E stains indicate differential progress during healing milestones. Periosteal reaction is more extensive in *Sostdc1*<sup>-/-</sup> compared to *WT* controls at D3 post-fracture (A, F). Chondrogenesis during early callus formation (D7) shows increased vascular invasion (arrow) in *Sostdc1*<sup>-/-</sup> mice compared to controls (B, G). Vascular invasion at D14 progresses to the middle of the cartilaginous callus in *Sostdc1*<sup>-/-</sup> mice, while neovascularization is occurring in the peripheral callus in *WTs* (arrows) (C, H). At D21, a thick cortical shell around the callus is evident in *Sostdc1*<sup>-/-</sup> mice (arrow), a reduced amount of trabecular bone formation in the interior of the callus is also present, and the original cortical bone is remodeling (arrow) while in *WTs* there is more trabecular bone, thinner cortical shell (arrow), and the original cortex remains unremodeled (D, I). Micro-CT analysis of 28-day calluses shows a greater callus volume in *Sostdc1*<sup>-/-</sup> ( $p < 0.005$ ) (E, J) (See also Table 2). p periosteum; cb cortical bone; ch chondrocytes; v blood vessel.







**Fig. 3.** Nestin and  $\alpha$ -smooth muscle actin co-localize with *Sostdc1* [using *LacZ* from the knocked in allele]. *LacZ*-stained bones show positive cells on the periosteal surface of the unbroken bone (A). *LacZ*-positive cells participate in the periosteal expansion at (B). This population of *LacZ*-positive cells expands into the undifferentiated callus tissue at D7 (C). *LacZ* expression in *Sostdc1*<sup>+/-</sup> mice is qualitatively reduced in intact periosteum, D3 and D7 fracture calluses, suggesting the pool of *LacZ*-positive cells is expanded in *Sostdc1*<sup>-/-</sup> mice (D-F). Dual marker immunofluorescent staining indicates the presence of both *LacZ* and

Nestin at the periosteal surface in unfractured femora, while there are fewer Nestin(+) cells in *Sostdc1<sup>+/-</sup>* (G, J). During the periosteal reaction, some cells expressing Nestin also show *LacZ* expression (H, K), while the two groups of cells are mutually exclusive in *Sostdc1<sup>+/-</sup>*. By D7, many cells in the undifferentiated callus region of *Sostdc1<sup>-/-</sup>* are positive for both markers, while substantially fewer double-labeled cells are present in *Sostdc1<sup>+/-</sup>* samples (I, L). [red  $\beta$ -galactosidase (*LacZ*); green Nestin (G-L); green  $\alpha$ -Smooth muscle actin ( $\alpha$ -SMA) (M-R)].  $\alpha$ -SMA is also shown in periosteum of unfractured femora of *Sostdc1<sup>+/-</sup>* and *Sostdc1<sup>-/-</sup>* mice (M, P). Cells and vessels positive for  $\alpha$ -SMA are much more abundant, have more dual label, and vessel are of a larger diameter in *Sostdc1<sup>-/-</sup>* mice at D3 post-fracture (N, Q). There is significant dual-labeling of undifferentiated cells in the D7 fracture callus of *Sostdc1<sup>-/-</sup>* mice, while there is very little overlap and very few  $\alpha$ -SMA-positive cells in *Sostdc1<sup>+/-</sup>* calluses (O, R). Quantitation of Nestin signal in D3 and D7 calluses of *Sostdc1<sup>-/-</sup>* mice revealed a significantly higher percentage of image area covered by Nestin(+) cells compared to *Sostdc1<sup>-/-</sup>* calluses at both time points (S). Quantitation of  $\alpha$ -SMA signal in D3 and D7 calluses of *Sostdc1<sup>-/-</sup>* mice revealed a significantly higher percentage of image area covered by  $\alpha$ -SMA -positive cells compared to *Sostdc1<sup>+/-</sup>* calluses at both time points (T). [p periosteum; cb cortical Bone; mc mesenchyme.]






**Fig. 4.** *SP7/Osterix (Osx)* osteoblast precursor levels are dramatically increased in *Sostdc1*<sup>-/-</sup> mice during fracture repair. Immunostains for *Osx* in *Sostdc1*<sup>-/-</sup> mice show an increased number of positive cells at the resting periosteal bone surface of unbroken bones compared to *WT* controls (A, D). The layer of cells that participate in the periosteal reaction at D3 post fracture is thicker and has more *Osx*-positive cells, especially at the periosteal surface, compared to controls (B, E). At D7 post-fracture, *Osx* levels are activated in developing intramembranous callus, which is larger and contains more positive cells in *Sostdc1*<sup>-/-</sup> mice, especially at the periosteal surface (C, F). Quantitation of signal area at D3 and D7 revealed an increased area of *Osx*-positive cells in *Sostdc1*<sup>-/-</sup> mice at both time points examined (G).



**Fig. 5.**

Quantification of mesenchymal stem cells (MSC) and osteoblasts (OB) populations during fracture repair. Purified MSCs from *Sostdc1*<sup>-/-</sup> femurs were found to express  $\beta$ -galactosidase, but no expression was detected in OB or endothelial (ENDO) cells, suggesting that *Sostdc1* is expressed in MSCs only (A). A time course quantification of MSCs (B) and OBs (C) determined that both MSC and OB expansion curves are shifted to the left, suggestive of earlier expansion of MSCs during fracture repair.



**Fig. 6.** Higher Levels of Activated  $\beta$ -catenin are detected in *Sostdc1*<sup>-/-</sup> mice during fracture repair. Immunostains for activate  $\beta$ -catenin in *Sostdc1*<sup>-/-</sup> and *WT* mice show increased  $\beta$ -catenin levels at the resting periosteal and metaphyseal bone surfaces in unbroken bones compared to *WT* controls (A, B, F, G). The layer of cells that participate in the periosteal reaction at D3 post-fracture is thicker and has more robust activated  $\beta$ -catenin compared to controls (brackets) (C, H). At D7 post-fracture,  $\beta$ -catenin is activated in the developing neovasculature, which is larger and more plentiful in *Sostdc1*<sup>-/-</sup> calluses compared to *WT* (brackets, arrows). Chondrocytes are negative for activated  $\beta$  -catenin (D, I). *Sostdc1*<sup>-/-</sup> show more activated  $\beta$ -catenin in woven bone at D7 post-fracture compared to controls (E, J). Negative controls stained with the secondary antibody only show insignificant background stain in the periosteum of both *Sostdc1*<sup>-/-</sup> (A') and *WT*(F') unfractured femurs [p periosteum; cb cortical bone; ch chondrocytes; v blood vessel; vb woven bone.]

TABLE 1

Bone Phenotyping Based on  $\mu$ CT Parameters in the Cancellous Bone Compartment of the Distal Femur, L4 Vertebrae and Cortical Bone of 5.5-Month-Old *Sostdc1*<sup>-/-</sup> Mice Compared to *WT* Controls.

	Index	<i>WT</i>	<i>Sostdc1</i> <sup>-/-</sup>
Femur	BV/TV (%)	9.50±1.20	6.50±2.00*
	Conn. Dens. (1/mm <sup>3</sup> )	155.827±13.975	108.507±38.540*
	SMI	2.284±0.225	2.502±0.326
	Tb.N (1/mm)	4.164±0.143	3.387 ± 0.397*
	Tb.Th (mm)	0.0399 ±0.0009	0.039 ±0.006
	Tb.Sp (mm)	0.227±0.009	0.292±0.035*
	BMD (mg HA/cm <sup>3</sup> )	913.452±14.108	935.367±15.824*
L4 Vertebrae	BV/TV (%)	19.90±0.80	12.80±2.40*
	Conn Dens. (1/mm <sup>3</sup> )	273.007±14.759	211.350±46.188*
	SMI	0.490±0.090	1.181±0.232*
	Tb.N (1/mm)	5.270±0.154	4.155±0.428*
	Tb.Th(mm)	0.036±0.001	0.035±0.002
	Tb.Sp (mm)	0.179±0.006	0.235±0.029*
	BMD(mg HA/cm <sup>3</sup> )	947.457±19.014	935.367±15.824*
Cortex	pMOI (mm <sup>4</sup> )	0.47±0.063	0.592±0.145*
	TA (mm <sup>2</sup> )	2.028±0.128	2.352±0.298*
	BA/TA (%)	42.80±1.80	40.00±2.00*
	MA (mm <sup>2</sup> )	1.161±0.089	1.414±0.208*
	Ct.Th (mm)	0.184±0.009	0.188±0.011
	BMD (mg HA/cm <sup>3</sup> )	1113.169±18.433	1132.091±17.407*

Data represents mean ± standard deviation for parameters measured. BV=Bone Volume; TV= Total Volume; Conn. Dens.= Connectivity Density; SMI= Structural Model Index; Tb. N= Trabecular Number; Tb.Th= Trabecular Thickness; Tb.Sp= Trabecular Separation; BMD= Bone Mineral Density; pMOI= Moment of Inertia; TA= Total Area; BA= Bone Area; MA= Marrow Area. Group size *n* = 5-10.

\* *p*-values < 0.05

**TABLE 2**

Histomorphometric analysis of Periosteal and Endocortical regions of 5.5 Month-Old *Sostdc1*<sup>-/-</sup> Femurs Compared to *WT* Controls.

Region	Index	<i>WT</i>	<i>Sostdc1</i> <sup>-/-</sup>	% change
<b>Periosteal</b>	MS/BS (%)	19.576±5.042	34.89±14.517*	+78
	MAR (µm/d)	0.025±0.005	0.019±0.005	-23
	BFR/BS (µm <sup>3</sup> /µm <sup>2</sup> /d)	1.794±0.667	2.333±1.115	+30
<b>Endocortical</b>	MS/BS (%)	47.023±9.881	51.185±13.328	+8
	MAR (µm/d)	0.027±0.004	0.016±0.003*	-42
	BFR/BS (µm <sup>3</sup> /µm <sup>2</sup> /d)	4.605±0.905	3.090±1.394*	-32

Data represents mean ± standard deviation for parameters measured. MS = mineralizing surface; BS = bone surface; MAR = mineral apposition rate; BFR = bone formation rate. Group size *n* = 6.

\*  
*p*-values < 0.05

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**TABLE 3**

Biomechanical properties determined by  $\mu$ CT and Torsional Testing of the Mature Callus Compartment of *Sostdc*<sup>-/-</sup> Mice Compared to *WT* Controls, at 28 Days Post-Fracture.

	Index	<i>WT</i>	<i>Sostdc</i> <sup>-/-</sup>
Callus	Callus Volume (mm <sup>3</sup> )	17.495±5.328	28.760±9.413 *
	BV (mm <sup>3</sup> )	3.804±0.966	5.197±1.042 *
	BV/TV (%)	23.30±0.88	19.10±4.40
	BMD (mg HA/cm <sup>3</sup> )	992.936±11.032	1022.581±11.220 *
Control	Stiffness (Nm/deg)	0.00171±0.0005	0.00192±0.0007
	Ult. Torque (Nm)	0.032±0.006	0.032±0.009
	Rot. Ult. Torque (degrees)	24.983±6.020	20.888±5.371
Fractured	Stiffness (Nm/deg)	0.00073±0.0005	0.00064±0.0003
	Ult. Torque (Nm)	0.021±0.009	0.018±0.005
	Rot. Ult. Torque (Degrees)	47.200±17.339	35.500±14.343

Data represents mean ± standard deviation for parameters measured. BV=Bone Volume; TV= Total Volume; BMD= Bone Mineral Density; Ult. Torque= Ultimate Torque at failure; Rot. Ult. Torque= Rotation at Ultimate Torque.

\* *p*-values < 0.05

Cell populations in the Femur during Fracture Repair in *Sostdc1*<sup>-/-</sup> Mice Compared to *WT* Controls.

**TABLE 4**

Days Post Fracture	(N)	Mesenchymal Stem Cells		Osteoblasts		Endothelial	
		WT	<i>Sostdc1</i> <sup>-/-</sup>	WT	<i>Sostdc1</i> <sup>-/-</sup>	WT	<i>Sostdc1</i> <sup>-/-</sup>
Unfractured	11	2.14±1.82	2.40±2.51	8.74±4.95	7.80±4.67	9.77±5.98	14.33±12.48
Day 5	4	1.98±0.68	5.50±1.67*	8.68±4.89	26.63±2.78*	5.77±1.99	11.32±5.7
Day 6	3	16.35±1.43	111.06±1.02*	36.31±5.89	44.49±10.83	17.03±2.92	15.98±6.59
Day 7	4	3.41±3.04	1.37±1.08	45.38±11.98	48.58±25.06	9.25±3.29	8.25±5.11
Area Under the Curve#		48.83	48.13	864.67	957.74*	129.95	168.96

Data represents mean percentages of cells in whole digested femurs ± standard deviation for parameters measured. All contralateral unfractured femurs for all time-points [days 5, 6, and 7] were averaged to obtain the unfractured values for *WT* and *Sostdc1*<sup>-/-</sup> mice.

\* *P*-values < 0.05;

# to calculate are under the curve unfractured values were used for day 0, day 14 [MSCs; ENDO] and day 35 [OBs] under the assumption that MSC and OBs would revert to unfractured levels at these time points (Figure 5B).